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Creation of the first national linked colorectal cancer dataset in Scotland:
prospects for future research and a reflection on lessons learned
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Current understanding of cancer patients, their treatment pathways and outcomes relies mainly on
information from clinical trials and prospective research studies representing a selected sub-set of
the patient population. Whole-population analysis is necessary if we are to assess the true impact of
new interventions or policy in a real-world setting. Accurate measurement of geographic variation in
healthcare use and outcomes also relies on population-level data. Routine access to such data offers
efficiency in research resource allocation and a basis for policy that addresses inequalities in care
provision.
Objective
Acknowledging these benefits, the objective of this project was to create a population level dataset
in Scotland of patients with a diagnosis of colorectal cancer (CRC).
Methods
This paper describes the process of creating a novel, national dataset in Scotland.
Results
In total, thirty two separate healthcare administrative datasets have been linked to provide a
comprehensive resource to investigate the management pathways and outcomes for patients with
CRC in Scotland, as well as the costs of providing CRC treatment. This is the first time that
chemotherapy prescribing and national audit datasets have been linked with the Scottish Cancer
Registry on a national scale.
Conclusions
We describe how the acquired dataset can be used as a research resource and reflect on the data
access challenges relating to its creation. Lessons learned from this process and the policy implications
for future studies using administrative cancer data are highlighted.
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Introduction
Administrative healthcare data – that is data collected as part
of a person’s routine healthcare - can provide information on
screening, surveillance, co-morbidities, diagnosis, treatments
and patient outcomes, as well as providing information on
the real-world cost of healthcare. Linking datasets together
provides more information than one dataset alone.
Cancer is a good example of where there is significant
potential to generate public benefit with administrative data,
specifically because of its high prevalence and disease burden.
Countries such as Denmark, Sweden and the Netherlands,
have a long history of using national registries for cancer
research [1–3]. Similarly, in the United States, the government
funded Surveillance, Epidemiology and End Results cancer
database program [4] is linked to Medicare records and this
data has been used widely to research patterns of cancer care,
the cost of that care and patient outcomes. These examples
scratch the surface of the enormous potential offered by going
deeper into linked health records.
In the United Kingdom (UK), administrative healthcare
datasets are generally held separately within the devolved
nations. In Scotland, a cancer registry collects information
on cancer specific variables such as date of diagnosis, type
and stage of cancer and an indication of the treatments
delivered. Although the registry offers a wealth of information,
it does not include detailed information on the names or doses
of systemic treatments delivered. It is therefore impossible
to accurately identify variation in management approaches
across the country, to understand the relative successes, or
to estimate the costs associated with treatment. Scottish
health service costs are publicised annually by sector, for
example as hospital, community or family healthcare costs,
but with no indication of how much is spent on cancer services
specifically [5]. To build up a full picture of what the cancer
trajectory looks like in Scotland, registry data must be linked
to other administrative healthcare datasets.
There are efforts in Scotland to streamline and improve
the use of cancer specific administrative datasets. For
example, the Cancer Medicines Outcomes Project (CMOP)
was commissioned by the Scottish government in response to
the 2016 Beating Cancer: Ambition and Action report [6]. The
overarching aim of this programme is to maximise the use of
electronic records to understand outcomes for patients treated
with cancer medicines in Scotland. One of the key objectives
of CMOP is to test the scalability of linking cancer medicines
datasets at a national level [7]. A separate major programme
of work, the Scottish Cancer Registry and Intelligence Service
(SCRIS) [8], was established in 2017 with the aim of creating a
national Cancer Intelligence Platform with national reporting
of cancer outcomes and treatments available to approved users
via a dashboard. In late 2020, chemotherapy prescribing data
(ChemoCare) covering 100% of the population was added to
this platform. Due to data privacy concerns, this system is not
intended to grant access to researchers to analyse individual
patient level data, rather its primary function is for use by
service providers in their delivery of cancer services in Scotland.
Recognising the gap that currently exists for researchers
to access and analyse national chemotherapy and other
healthcare administrative data, and considering colorectal
cancer (CRC) specifically, we have focused on acquiring and
linking administrative datasets in Scotland, including granular
treatment records. Worldwide, colon and rectal cancer are the
fourth and eighth most common cancers and causes of cancer
deaths respectively, with over 1.8 million cases diagnosed each
year [9]. It is estimated that at least e13 billion is spent on
CRC care in the European Union alone each year [10]. The aim
of this project was to create a linked dataset to allow mapping
of the CRC landscape in Scotland and to identify differences
in treatment pathways and the outcomes associated with
different treatment approaches. This would enable practices
with the best outcomes to be replicated and any variation
in treatments to be addressed. In addition, the ambition was
to use the dataset to provide a description of the real-world
interaction of cancer patients with the Scottish healthcare
system and to calculate the cost of healthcare resource use
required for CRC diagnosis and management on a national
scale.
This project is a part of a larger initiative, the
Cancer Research UK (CRUK) funded COloRECTal Repository
(CORECT-R), which is a UK wide programme aiming to
quantify the characteristics of, and any variation in, CRC
and its management [11]. One of the major work-streams
for CORECT-R is to create a single colorectal research data
system to enable analysis of data collected across all four
UK nations. Due to the distinct data governance regulations,
organisations and databases in devolved nations, the process
of accessing and linking cancer datasets is being performed
in parallel in each nation. This project represents the Scottish
arm of that work-stream and has a particular focus on using
the Scottish data to investigate the health economics of CRC
care.
The aim of this paper is to document the process of
creating this disease specific cancer dataset for research in
Scotland. Specifically, we:
1. Outline the datasets available for this purpose in
Scotland
2. Describe the current data linkage infrastructure in
Scotland and provide an overview of the processes and
timelines involved in successfully accessing and linking
data
3. Describe the potential for use of these data in future
for patient and public benefit and summarise the key
challenges we encountered.
Methods
Navigating the administrative data linkage
infrastructure in Scotland
In Scotland, since the 1970s, on first registration to
the healthcare service every patient is assigned a unique
Community Health Index (CHI) number. A CHI number
consists of a patient’s date of birth plus four additional digits.
CHI numbers are beneficial in terms of data linkage because
they serve as a unique identifier across a range of healthcare
datasets. This is one reason why Scotland is particularly suited
to linking its health records for research purposes.
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Datasets relevant to this project
The datasets that are included in the CORECT-R Scotland
specification are outlined in Table 1. Several datasets are
held centrally and governed by Public Health Scotland (PHS,
previously the Information Services Division (ISD) in National
Services Scotland (NSS)), whereas others are held by external
data controllers. Systemic anti-cancer therapy prescriptions
and Cancer Quality Performance Indicator (QPI) data in
particular, are held at local or regional levels, with no central
repository. An arbitrary time-point (2006) for the earliest
Cancer Registry records accessed was chosen to allow at least
10 years of follow up after the first patient cancer diagnosis.
Datasets providing information on deaths or cancer diagnosis
were also requested from 2006. Inpatient and outpatient
resource use datasets were requested from 1997 to allow
analysis of resource use prior to a cancer diagnosis and to allow
calculation of the Charlson co-morbidity index using data from
five years prior to diagnosis. Any dates of access beginning
after 2006 were dictated by the years of data available for
those specific datasets.
Additional information on co-morbidity, provided as the
Charlson co-morbidity index [12], socio-economic deprivation,
provided as Scottish Index of Multiple Deprivation (SIMD) and
the Carstairs and Morris Index [13, 14], as well as rurality of
patient’s residence, is provided by PHS as derived variables
included within a number of the above named datasets.
Patient level information cost system (PLICS) variables are
currently available for individual episodes of care within a
number of SMR datasets but there are currently no PLICS
variables linked with the cancer registry and little work has
been undertaken to assign costs to cancer care specifically in
Scotland.
Key stages in accessing and linking datasets
There were four main stages (Figure 1) in accessing and linking
datasets on a national level. In what follows, we describe the
processes undertaken for the datasets that have already been
successfully linked for this project.
Stage 1
The first stage in accessing data was to define the study
requirements in order to apply to the Public Benefit and
Privacy Panel (PBPP) for Health and Social Care in
Scotland [15]. PBPP have responsibility for weighing up the
benefits to the public from granting access to healthcare data
against the risk that the sharing of the data poses to an
individual’s privacy. All applications to PBPP go to a Tier
1 panel for proportionate review. Some applications will be
referred on for further review by a Tier 2 Committee. There
are lay representatives who assess submissions at both Tiers.
The application for this project was reviewed at Tier 2. A
separate application was required to access SICSAG data and
this was submitted to the SICSAG Steering Committee.
Stage 2
The second stage of the project was acquisition of datasets for
transfer into the National Safe Haven (NSH). The NSH is a
research platform operated by Edinburgh Parallel Computing
Centre on behalf of PHS. The NSH provides a secure analytical
environment where data controllers can allow administrative
data to be used for research purposes when it is not practical
to obtain individual patient consent, whilst protecting patient
privacy and identity. eDRIS were the principal department
of PHS responsible for overseeing data transfer. During this
second stage, clarification of the content of the datasets
required a PBPP amendment, which also included a clearer
explanation of the cohort generation and indexing process.
Datasets held by PHS (Table 1) did not require transfer
because they are already held centrally within NSS. Figure 2
shows the data transfer process that occurred to transfer data
externally from PHS to eDRIS, and internal data within PHS.
A trusted third-party indexing team (CHI Indexing and Linkage
Service (CHILIS)) facilitated transfer for the cohort generation
and indexing of datasets. This third party and extra step
was required to ensure the privacy of patient information.
Specifically, this meant that no identifiable data was sent
directly from data controllers external to PHS to the eDRIS
team. Instead, patient identifiers were replaced with a unique
patient identifier and the data was subsequently considered
pseudonymised because the link between unique identifiers and
CHI numbers was held by a trusted third party (CHILIS). In
addition, under General Data Protection Regulation (GDPR),
health data is considered sensitive category personal data and
therefore cannot be considered fully anonymised. The cohort of
patients included in the final dataset (Figure 2 “Master Cohort
List”) was defined using a combination of Cancer Registry and
chemotherapy prescribing data.
Stage 3
Each dataset that was to be released to the research team
for analysis was checked by eDRIS to confirm it matched the
approved specification. This checking followed a series of steps
and was repeated as required if any issues were identified.
After the main analyst completed the extraction, a second
analyst checked the coding used. The research co-ordinator
then checked the data files and confirmed that each approved
researcher had submitted the required documentation to
grant access to the data (detailed below). Once the data
files were ready for release and the researchers met their
required obligations, the co-ordinator requested final checks
and authorisation of release from a senior manager who had
permission to fulfil that role.
Deterministic linkage of pseudonymised datasets was
performed by the eDRIS team within their NSH using
individual unique identifiers. Essentially each of the unique
indexed identifiers supplied in Step 4 of Figure 1 was replaced
with the master index in Step 7 so each patient had the
same unique identifier across all datasets. Final checks on the
linkage step was also done by eDRIS prior to release into the
designated project area within the NSH.
Stage 4
After linkage was performed, the pseudonymised dataset was
transferred to the researcher-facing NSH. Access to data
within the NSH was limited to the project team named
on the most recently approved PBPP application. Prior to
accessing the data, each named person demonstrated up to
3
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Table 1: Datasets included in the CORECT-R Scotland specification




NRS Deaths NRS This dataset is collected by National Records Scotland
(NRS), which is a Scottish government institution. It contains
information on date, cause and place of death for all deaths
registered in Scotland since 1974. PHS is granted access to




PHS This dataset contains patient level episode data on outpatient
appointments across all specialities (except A & E and
Genito-urinary medicine). Data collection began in Scotland





PHS SMR01 comprises patient level episode data on hospital
inpatient and day case discharges from acute specialities in




PHS SMR04 contains data for patients receiving care in Mental




PHS SMR06 is also known as the Scottish Cancer Registry and was
established 1954. This dataset collects information relevant
to the diagnosis and management of malignant neoplasms,
as well as carcinoma in situ and some benign tumours. Data
is collected annually. CORECT-R Scotland has requested
information on patients with a diagnosis of CRC only. This
dataset contains CRC staging information based on both







Regional chemotherapy prescribing dataset. ChemoCare is the
electronic data system that captures prescription of systemic
anticancer agents and supportive medications in hospitals in
Scotland. This does not include all hospital prescriptions, and
would not, for example, include medications written on a
drug prescription chart for patients during an inpatient stay.
It would provide information on chemotherapy and supportive
medications received by a patient whether they received that






































National prospective audit dataset collected and stored
regionally on an annual basis (April each year). NHS boards
are required to report their activity against QPIs as part of
a mandatory national cancer quality programme. Healthcare
Improvement Scotland is responsible for the external quality
assurance of cancer services against tumour specific QPIs.
This dataset contains CRC staging information based on
both TNM and Duke’s staging classifications. It also includes
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Table 1: Continued












National prospective audit dataset (as for WoS). 2013–2018
Costs (PLICS) PHS PLICS is the patient level information costing system and
contains cost variables derived from SMR00, SMR01 and
SMR04. This top down costing system was developed to allow
hospital costs to be attributed to patient activity in a detailed
way to reflect key cost drivers such as length of stay. PLICS
apportions hospital site and speciality specific direct costs to
individual patient records on admission, per day, for theatre









SICSAG is the Scottish Intensive Care Society Audit Group
dataset and contains both episode level and daily information
provided for each patient.
2006–2018
Radiotherapy NA Detailed radiotherapy data is currently not available on
a national basis in Scotland and instead is held loco-
regionally by radiotherapy centres. Key information on
radiation treatment delivered (for example if radiotherapy was
delivered and date of treatment) is currently available within
the Scottish Cancer Registry (SMR06). However, granular
radiotherapy data (for example dose, technique and modality)
is currently held by individual hospital institutions which
deliver radiotherapy. A process is in development to make
radiotherapy data available nationally – this involves Scottish
radiotherapy centres sending data extracts to Public Health
England, who curate the data to a common standard prior to






PHS The Prescribing Information System (PIS) is a data source
for all prescribing of medicines (and their costs) that are
prescribed and dispensed in the community in Scotland. This
includes medications prescribed in hospital but dispensed
in the community but not those dispensed in hospital.
Information for this dataset is supplied by the Practitioner




PHS This dataset was originally established in 2007 to monitor
compliance of each NHS board with the maximum four
hour waiting time target. Departments may submit individual
episode level data (detailed information on each patient
attendance) or aggregate level data (often smaller minor
injury units). Sites that submit episode level data account
for 94% of national A and E attendances.
2011–2018
GP Out of Hours PHS A Scottish government commissioned (2014) dataset to
improve understanding of activity, demand and capacity at





PHS The SAS dataset contains individual level records of all
patient contact with the service.
2011–2018
NHS 24 PHS The NHS 24 dataset contains individual level records of all
patient contact with the service.
2011–2018
Abbreviations: NRS, National Records Scotland; SMR, Scottish Morbidity Records; A&E, Accident and Emergency; PHS, Public
Health Scotland; QPI, Quality Performance Indicator; WoSCAN, West of Scotland Cancer Network; SCAN, South East Scotland
Cancer Network; NoSCAN, North of Scotland Cancer Network; PLICS, Patient Level Costing System; NHS, National Health
Service; GP, General Practitioner; SICSAG, Scottish Intensive Care Society Audit Group; PIS, Prescribing Information System;
SACT, Systemic Anticancer Therapy; ASA, American Society of Anaesthesiologists; TNM, Tumour, Nodes, Metastases.
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Figure 1: Flowchart outlining the main stages to access and link data
Abbreviations: NSH, National Safe Haven; eDRIS, electronic Data Research and Innovation Service; PHS, Public Health Scotland;
QPI, Quality Performance Indicator; SICSAG, Scottish Intensive Care Society Audit Group; CHILIS, CHI Indexing and Linkage
Service; SMR, Scottish Morbidity Record; PBPP, Public Benefit and Privacy Panel for Health and Social Care.
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Figure 2: Cohort definition and transfer of datasets to Public Health Scotland
Abbreviations: PHS, Public Health Scotland; QPI, Quality Performance Indicator; CHILIS, CHI Indexing and Linkage Service;
eDRIS, electronic Data Research and Innovation Service; CHI, Community Heath Index; SICSAG, Scottish Intensive Care Society
Audit Group; PLICS, patient level information costing system.
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date, approved information governance training and completed
an eDRIS User Agreement, which stipulated the framework
for data access and was signed by the named researcher’s
organisational lead. A requirement for working with this linked
data in future will be that all outputs (for the purposes of
internal discussion within the research team and/or for public
dissemination of research findings) must undergo a disclosure-
controlled release. For this to occur, it will require two eDRIS
employees to check the outputs, one of whom has special
authorisation to approve data for release from the NSH.
Results
Datasets accessed and linked
At the time of writing, ’release one’ and ‘release two’ of
the data are currently available within the NSH for use by
named project researchers. Interim datasets for release one
were available in April 2020, prior to confirmation of the
linkage step, and fully available at the end of July 2020.
Release two was available in December 2020. These data
releases contain information on 47,157 patients diagnosed with
CRC in Scotland and links thirty-two separate datasets and a
demographics file. This information represents the majority of
the administrative data approved for this project by PBPP
(see Table 1 for full list) and access to the remaining datasets
for unscheduled care data is pending. Figure 3 provides an
overview of the data sources and the number of patients
included in each of the datasets obtained thus far. The final
master cohort contains information on all patients aged 18+
who had a CRC diagnosis between January 2006 and April
2018 in Scotland.
Overall timings
First contact with an eDRIS co-ordinator was made in January
2018 and the PBPP application was submitted in April 2018.
PBPP approval was granted in October 2018 after Tier 2
review by a full panel of PBPP committee members. Therefore,
Stage 1 took approximately 9 months in total. A substantial
amendment was necessary and this was approved in February
2020.
Stage 2 (data acquisition) took approximately 1.5 years.
Figure 4 provides a more detailed time-line for this part of the
process. It involved initiating and continuing a dialogue and
discussion with the relevant data controllers/data providers
in the NHS Boards and other analytical teams in PHS.
The ChemoCare and QPI datasets required the use of a
secure transfer platform to transfer the data into PHS.
To facilitate this, both ChemoCare and QPI data providers
were given separate login details and passwords to access
this platform when they transferred data to CHILIS versus
eDRIS. In total, 28 successful secure transfers were performed
(see Figure 2) to transfer data from external data providers
to PHS.
Organisation of datasets and linkage by eDRIS took
approximately ten months. Finally, stage four was transfer of
the data to the NSH to be analysed by the researchers. In total,
from first contact with eDRIS to access release one of the
data by the researchers was around 2.6 years and from PBPP
approval to data access was approximately 1.9 years. Access to
release two of the data was made available five months after
release one.
Estimated direct costs and resource use
incurred during this process
An estimation of the costs and resource use required to
achieve data access so far for the purposes of this project
are outlined in Figure 5. Many of the individuals were
involved over the majority of the 2.6-year period. From the
perspective of the institution facilitating data access, the
main study was considered a bespoke large project for costing
purposes. A closely aligned PhD project, submitted for PBPP
in parallel with the main project, was charged at a small project
rate.
Discussion
Population-level administrative data sets offer significant
potential to add to our understanding of how patients interact
with health care services and provide a detailed picture
of the care they receive. Data on a whole nation allows
the characterisation of variation in disease management and
clinical pathways, potentially identifying opportunities for
more efficient resource allocation and improved care. Access
to this type of data however, has been a significant challenge
for researchers.
We have demonstrated, using CRC in Scotland as an
exemplar, that the creation of a national linked administrative
dataset, spanning more than ten years and collated from
multiple data providers, is now possible, albeit with substantial
efforts and extensive collaboration between researchers and
the central team co-ordinating and performing data transfers
and linkage. In particular, we have linked regionally held
individual patient chemotherapy prescribing data (including
co-prescribed medications) and quality performance data for
cancer services to other nationally held health care datasets
for all CRC patients in Scotland (2006–2018). This is a
novel accomplishment. QPI data will be particularly beneficial
in ensuring the robustness of any analysis given that it is
prospectively collected according to a national proforma and
all data entry undergoes validation. Accessing and linking
chemotherapy prescribing data has been uniquely challenging
because it is held in hospitals within digital prescribing systems
that are not linked to the community prescribing platform
that currently exists. Indeed, even in Scandinavian countries
with a strong history of successful data linkage, accessing
systemic anti-cancer treatment data on a national basis and
linking it to the central cancer registry has been identified as
a challenge [16, 17].
By describing the process of creating such a dataset in
Scotland, we hope that we can facilitate data access for future
researchers. We also want to allow comparison between our
strategy and other important programmes of work (such as
C-MOP and SCRIS in Scotland), to improve transparency and
promote collaboration on a Scotland, UK or wider basis within
the discipline of real-world data analysis for public and patient
benefit.
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Figure 3: Datasets included in release one and two with the number of patients contained in each dataset
Abbreviations: ICD, International Classification of Disease; CRC, Colorectal cancer; WoSCAN, West of Scotland Cancer Network;
SCAN, South East Scotland Cancer Network; NoSCAN, North of Scotland Cancer Network; SMR, Scottish Morbidity Record;
QPI, Quality Performance Indicator; NRS, National Registry Scotland; SICSAG, Scottish Intensive Care Society Audit Group; PIS,
Prescribing Information System; PLICS, patient level information costing system.
Future research opportunities using this
dataset
For the first time, this dataset will allow a description of
the real-world patient characteristics, treatment pathways,
outcomes and cost of treating CRC in Scotland. Previously this
has not been possible due to the lack of detailed prescribing
information included in the Scottish Cancer Registry. Initial use
of the data will be to describe the cohort of patients diagnosed
with CRC in Scotland and the treatments they receive, with
9
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Figure 4: Timeline for transfer of datasets to PHS. As of January 2020, 32 individual data files were available
There was also a demographics file which contained all patients in the master cohort, which was provided to the research team with
release one of the data. PIS datasets were provided as nine separate data files, one for each year (2010–2019). ChemoCare Grampian
and Highlands data were provided each as three separate files. ChemoCare Grampian provided an additional file with information
regarding body surface area, height and weight. SICSAG information consisted of two files (episodes and daily information).
Abbreviations: WoSCAN, West of Scotland Cancer Network; SCAN, South East Scotland Cancer Network; NoSCAN, North of
Scotland Cancer Network; QPI, Quality Performance Indicator; NRS, National Registry Scotland; PIS, Prescribing Information
System; A&E, Accident and Emergency; GP, General Practice; SICSAG, Scottish Intensive Care Society Audit Group.
a specific focus on variation and the identification of outliers.
This will be followed by a specific focus on post-operative
treatment with the aim of understanding if management
heterogeneity exists in Scotland, as previously demonstrated
in England [16], and what this means for healthcare service
costs. A subset of this dataset will be used to investigate
the impact of clinical trial findings in the real world setting
(PBPP application number 1718-0263) and the budget impact
of implementing trial findings on a national scale.
A research repository as a future model for
rapid data availability
The current model for access to administrative health care
data in Scotland is one of ‘link and destroy’ for individual
research projects [17]. In this way, multiple researchers might
apply for the same or similar data to be linked, but this is
all done in silos. Although it addresses many of the privacy
concerns from data controllers, it is not an efficient use of data
providers’ resources or researchers’ time. This type of model
may pose a threat to scientific progress, research integrity and
transparency, in the sense that it is difficult to reproduce results
that have stemmed from a bespoke linked dataset which has
subsequently been destroyed.
Recent developments within the Scottish Government
recognise the potential benefits of preserving the linkage
between datasets and storing data indefinitely for use by
multiple research projects, whilst maintaining appropriate
information governance protocols. This avoids duplication
of data linkage and cleaning required for the initial
10
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Figure 5: Direct costs and resource use
Abbreviations: eDRIS: electronic Data Research and Innovation Service, PhD: Doctor of Philosophy, QPI: Quality Performance
Indicators, SICSAG: Scottish Intensive Care Society, CHILIS: CHI Indexing and Linkage Service, PHS: Public Health Scotland,
PLICS: Patient Level Information Costing System, PBPP: Public Benefit and Privacy Panel for Health and Social Care.
linkage and preparation. Specifically, Research Data Scotland
was launched in 2019 as part of the Programme for
Government [21]. This is a not for profit organisation which
aims to improve the economic, social and environmental
wellbeing of Scottish residents by enabling access to linked
data, not limited to healthcare datasets, for research in
the public good. Further developments within this sphere
in Scotland are also developing locally [18]. Research data
repositories have the advantage of enhancing research integrity
and transparency, since the reproducibility of research is
maintained. Indeed, the UK Colorectal Cancer Intelligence Hub
programme, of which this project is part, has developed the
CORECT-R for English data, and other non-cancer examples
exist [19].
We have seen during the Covid-19 pandemic how critical
it is that researchers can access data in a timely manner
to address urgent, real-world research questions. Looking
to the future, preserving the linked CRC datasets we have
established for this project should be considered essential
to support research and inform clinical practice. At present,
resources necessary to link datasets are potentially prohibitive
for future researchers seeking to carry out research projects
using individual patient level chemotherapy data on a national
scale in Scotland. It would therefore be in both patient and
public interest to preserve the dataset as a repository to which
future researchers could apply. As a further step, linking this
repository with the CORECT-R in England would increase the
strength of any conclusions drawn from the Scottish data
by allowing analysis of costs and outcomes relevant to a
much larger group of patients and by making cross-country
comparisons. Attempts to link these English and Scottish
datasets are being pro-actively pursued.
Challenges
Alongside the successes and potential use of this information,
we have experienced a number of unforeseen challenges
that arose in the process of achieving access to this novel
dataset. We believe that if similar issues are repeated in
future, this may lead to important research with potential
public benefit not being undertaken. Whilst this harm
is difficult to quantify, others have documented concerns
over the non-use of health data in research [20]. There
is a significant patient voice in favour of making patient
records available for research which is now overshadowing
concerns over privacy that have headlined in the mainstream
media [21]. Our intention is not to undermine any of the
information governance processes that currently exist, but to
address barriers to safe researcher access that we believe are
disproportionate.
Data specification
No national data dictionary existed to describe the information
that is held in each ChemoCare system. This made dialogue
with ChemoCare analysts to plan the project specification
more difficult, ultimately leading to the requirement for a
substantial PBPP amendment to reflect the actual data
received versus the variables originally requested and approved.
We have partly addressed this problem by disseminating
a list of the core variables held in all ChemoCare
systems across Scotland [22] as part of a larger data
dictionary describing all variables in release one of the
data.
11
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Table 2: Recommendations for creating a linked healthcare dataset
Recommendation∗
Data specification Data dictionaries for datasets being linked are a requirement to record in advance, which data variables will
be accessed and linked.
Capacity Investment is required to ensure sufficient staff capacity at regional sites so that resource is not being diverted
from service provision for the purpose of research and development without proper recognition of this effort.
This is an urgent requirement specifically for ChemoCare sites in Scotland.
Data transfer All parties involved (for example, data controller or analyst transferring data, the institution accepting the data
and a third party) in a data transfer from a regional to central site need to prioritise communicating effectively
within the same time window (often 2-3 days) regarding a data transfer if the data transfer is to be successful.
A secure data transfer platform is required. It should be straightforward to use by central and regional data
analysts, with ready access to information technology support if any technical issues arise (such as resetting
passwords).
Data linkage Easier data linkage would be possible if the data being linked was held by a central data controller. Data held
by different regional data controllers makes data transfer and linkage more difficult. This was demonstrated in
our work for ChemoCare and QPI datasets.
Data Access A secure research environment to store and analyse data is required to meet data governance and privacy
requirements. The Scottish National Safe Haven is one example of this type of research environment. Others
exist and some are industry-led, for example, AIMES Management Services Ltd.
Preserving linked data, such as the datasets described in this project, as a repository should be a priority. This
will facilitate data access for future researchers and reduce wastage of resources.
Resources Training of staff at regional sites is required to ensure they have the skills required for efficient extraction,
analysis and transfer of large datasets. These staff also need access to proper information technology
infrastructure that can deal with large datasets. This is particularly urgent for ChemoCare sites in Scotland.
Staff capacity at central sites needs to be sufficiently robust so that there is no slowing of data transfer
and linkage set-up due to external pressures such as annual leave/sickness/other projects. There should be
continuity in the staff managing data transfer and linkage.
A co-ordinating team whose role is to oversee and organise information governance approvals, data transfer
and linkage helps to streamline the process.
∗Regional datasets= the same information for different locations within the same country are held by individual data controllers
at a regional level, for example ChemoCare datasets. Regional sites= the organisations holding regional datasets. Central
datasets= datasets which are stored and maintained at a national level, for example SMR datasets in Scotland. Central sites= the
organisations holding central datasets.
Capacity
The length of time required to obtain ChemoCare datasets in
particular was also partly attributable to a lack of capacity
for staff within regional cancer networks to engage with the
process. The responsibility for physically downloading reports
from the ChemoCare system was often performed by an
individual whose major responsibility was service provision.
In addition, one ChemoCare site had specific difficulties with
the software required to store large datasets. In future,
ChemoCare and/or QPI data should be stored centrally, as
is the case currently for SMR datasets in Scotland and
as occurs currently with the Systemic Anti-Cancer Therapy
database in England [23]. This would significantly enhance the
ease of any linkage of chemotherapy datasets in future. We
suggest that investment should be made to help realise this in
Scotland.
Data transfer
Each transfer of data from data providers external to PHS
required careful communication between the sender and
the recipient because data deposited in the secure transfer
environments was automatically deleted if not picked up within
72 hours. Launch of a new secure file transfer system coincided
with the data transfer and indexing process (stage 2) and
at times, it was necessary to utilise a second, separate data
transfer platform because of problems with the new system.
In addition, the fact that the project’s master cohort was
defined by both SMR06 as well as five ChemoCare cohorts,
meant that transfer of ChemoCare data required additional
transfers for each site compared to if SMR06 alone was being
used.
Data linkage
Once the datasets had all been transferred to eDRIS, data
linkage took longer than anticipated because the first attempt
at linkage experienced technical problems. The time between
the first and second linkage was approximately four months.
This unexpected difficulty was partly due to the number of
datasets being linked and the impact of the Covid-19 pandemic
when resources reprioritisation was required within PHS.
Data access
The dataset we describe in this paper represents most of the
full dataset that was approved, although unscheduled care data
is still not available. It had been anticipated these datasets
12
Hanna, CR et. al. International Journal of Population Data Science (2021) 6:1:10
would be included in release two, and the delay is partly a
result of competing resources due to the pandemic.
Resources
A substantial portion of the time-line stipulated by the funder
for this project was dedicated to data access. The timeliness
of data access has previously been documented as a barrier in
several other UK projects [24, 25] and raises a broader issue
around the ability of early career researchers to use nationally
linked cancer datasets that include chemotherapy data in
Scotland within the current landscape. We have outlined that
the cost for data access correlates with the number of datasets
external to PHS being linked, which also makes it infeasible for
an early career researcher to use data that relies on bespoke
project-specific linkage.
Regulatory changes and external forces
Several unforeseen regulatory changes and events occurred
during the project that caused delays. For example, at the
time of submission, the legal requirements to demonstrate
that accessing data complied with the European Union GDPR
changed and required alteration of the submission documents.
Moreover, changes to the key institutions co-ordinating data
transfer and access took place during the project. For example,
the NSS Information Services Division changed to Public
Health Scotland. Finally, the onset of the global Covid-19
pandemic affected working environments and led to an acute
increase in workload for PHS from approximately March 2020
as they justifiably prioritised research classified as part of the
health service response to the pandemic. Although these issues
are specific to this project, it is strongly recommended that
the occurrence of similarly unforeseen events are anticipated
with any similar projects in future and flexibility in timelines is
incorporated to account for this possibility.
Reflecting on the successes and lessons learned from this
process, Table 2 outlines our recommendations for conducting
this process for other tumour types in future. In particular,
these suggestions are aimed at reducing many of the delays
we encountered and streamlining this process.
Conclusion
The siloed nature of modern healthcare is clearly detrimental
for sharing learnings and improving care. This is evidenced
in numerous ways throughout the NHS and is not conducive
to optimising patient care. We have outlined our experience
over several years to access national level chemotherapy
prescribing data for a single tumour type, linked with several
other datasets in Scotland, and deposited in an anonymised
format specifically for research use. We strongly believe that
transparent communication around the efforts that are ongoing
to improve access to administrative data for the purposes
of research are essential if we are to learn from previous
failures and successes. We hope that describing this process
will benefit researchers, the institutions helping to provide
and co-ordinate linkage of administrative cancer information,
the data controllers and ultimately patients who will gain
from discoveries made using this data. We feel that setting
up this linked dataset has been a valuable investment given
the huge potential public and patient benefit from using real
world cancer data to improve patient outcomes and service
delivery. We welcome any efforts by national policy makers
to streamline this process going forward and we hope this
project can serve as the basis for future work to build a better
landscape for administrative cancer data linkage, storage and
access in Scotland.
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